Six months into 2026, the dental economy is telling two stories at once. Demand for care remains fundamentally resilient, Americans spent $189 billion on dental care in 2024, tied for the highest annual total this century, and consumer dental spending was up roughly 4% year-over-year as of early 2026 (ADA Health Policy Institute / CMS). At the same time, the economics of actually delivering that care have rarely been tighter. The ADA’s Health Policy Institute has formally dubbed the current environment a “fiscal squeeze”: practice expenses rising faster than reimbursement, with no relief in sight.

At Revere Partners, a venture capital fund focused exclusively on oral health, we see this tension not as a crisis but as the single greatest catalyst for dental technology adoption in a generation. When labor is scarce, reimbursement is flat, and consolidation is accelerating, software stops being a luxury and becomes the operating system of survival. Below are the five forces our investment team is tracking at mid-year  and how each one informs where we are deploying capital. 

1. The Margin Squeeze: Why Practices Now Buy Efficiency 

Market reality. Dental practices are caught between rising overhead and stagnant insurance reimbursement. ADA HPI data show dental equipment and supply prices rose approximately 5% in just the first five months of 2025, with most practice owners reporting increases beyond that while reimbursement rates have barely moved. Industry analysts estimate supply costs are now rising at roughly three times the rate of insurance reimbursement growth. Labor tells the same story: even with record dental hygiene program graduation numbers in 2025, total dental office employment has remained stubbornly flat, and dentists have rated hygienist recruitment as “very” or “extremely” challenging for three consecutive years (ADA HPI). In HPI’s most recent quarterly panels, staffing, insurance, and overhead costs were the three most frequently cited concerns among practice owners.

The most telling data point of the half-year: while only 16.9% of dentists planned new software investments in Q4 2025, 24.4% had actually made them by Q1 2026. When practices cannot afford to hire efficiently, they buy it.

The Revere POV. This is the ultimate tailwind for B2B dental SaaS. We are prioritizing companies that automate the revenue cycle and the front desk, eligibility verification, claims, scheduling, recall as integrated layers within the practice management system, rather than point solutions that add yet another login. We are also prioritizing clinical technologies that make a tangible, financial impact. The winners of this cycle will be enterprise-wide platforms that let a practice produce more with the same headcount. Our portfolio strategy reflects this conviction: efficiency software is no longer a discretionary purchase; it is the only lever practice fully controlled.

2. Elective Dentistry’s Trust Gap: The Case Acceptance Opportunity

Market reality. Consumer dental spending is robust in aggregate, but high-margin elective dentistry, clear aligners, implants, and full-arch restorations  is where economic anxiety shows up first. Cost remains the number one reason patients decline or delay treatment (ADA HPI), and benchmark data from Planet DDS’s 2025 Dental Industry Outlook, drawn from 3,400 practices, found that nearly half of practices report case acceptance rates between just 40% and 70%, with average case completion at only 42%. Patients increasingly treat large elective treatment plans as financial risks, and the market has responded with a visible surge in point-of-care financing: buy-now-pay-later platforms purpose-built for dentistry now report patient approval rates near 90% and meaningful, measurable lifts in treatment conversion.

The Revere POV. The opportunity is the “digital front door” and the case acceptance stack. Startups building 3D treatment simulators, AI-driven visual diagnostics that let patients see their own pathology, and embedded fintech that turns a five-figure quote into a manageable monthly payment are giving patients the radical upfront transparency they now demand. Revere was early to this thesis. Our fund has committed to dental fintech, backing companies modernizing how patients pay for care  and we continue to believe the practices and platforms that pair clinical visualization with frictionless financing will maximize the revenue produced per hour of chair time. Provider upskilling and case presentation training are the underrated multipliers here, and we look for companies that build education into the product.

3. AI Remains the Operational Antidote and Capital Agrees

Market reality. Industry trackers put dental tech venture funding at roughly $2.1 billion in 2025, up about 18% from 2024, capital flowing disproportionately toward solutions that offset the labor shortage. Clinical AI has crossed from novelty to standard of care: Pearl, Overjet, and VideaHealth all hold FDA 510(k) clearances, with Pearl and Overjet together accounting for roughly a third of all dental AI clearances issued to date. The results are commercial, not just clinical, vendors report double-digit lifts in disease detection and case acceptance, and the first half of 2026 has already seen major DSO-wide and international AI rollouts. The funding momentum has carried into 2026: recent rounds include VideaHealth’s $40 million Series B and  Archy’s $20 million Series B for an AI-native practice management system.

The Revere POV. We believe FDA-cleared diagnostic autonomy is becoming table stakes: it instantly boosts case presentation credibility and, by extension, revenue. But the era of standalone AI point tools is ending. The winning platforms will combine clinical intelligence with deep, native integration into practice management systems, where the diagnosis, the treatment plan, the insurance claim, and the patient communication live in one workflow. Office management is becoming inseparable from production, and marketing spend is increasingly tied directly to patient engagement data. We are investing accordingly: in AI that touches both the clinical and operational sides of the practice at once.

4. The PE Specialty Premium: Software Follows the Consolidation Playbook

Market reality. The private equity DSO consolidation engine remains hungry, and its appetite has shifted upmarket. With general dentistry increasingly consolidated, capital is moving into oral surgery, orthodontics, endodontics, and pediatric dentistry, specialties with higher margins and higher barriers to entry. Current market data show general single-location practices trading at roughly 5–7x EBITDA, while specialty practices command 8–15x, with premium multi-site specialty platforms reaching higher still. The structural setup for the next twelve months is significant: platforms acquired in the 2020–2021 vintage wave, held through the high-rate environment of 2023–2024, are now approaching the end of typical five-year hold periods just as rates ease. Industry analysts broadly expect a surge of recapitalizations and platform trades in 2026, and our own conversations across the DSO landscape suggest the large majority of sponsor-backed platforms are actively preparing for a liquidity event in the near term.

The Revere POV. Software follows the PE playbook. Tech stacks purpose-built for multisite DSOs, centralizing revenue cycle, credentialing, supply procurement, and analytics; driving same-store organic growth without proportional overhead; and seamlessly onboarding high-value specialty providers  directly protecting and expanding the EBITDA multiple a sponsor can command at exit. We view this category as “exit insurance” for PE, which makes it both a venture opportunity and a natural buy-and-build acquisition target. Revere’s deep relationships across DSOs give our portfolio companies a distribution advantage in exactly this segment.

5. Regulation Meets Innovation: Compliance Is the New Growth Vertical

Market reality. State governments meaningfully stepped up scrutiny of healthcare M&A and corporate dentistry over the past twelve months. California’s AB 1415 and SB 351 took effect January 1, 2026, expanding the state’s transaction review process to require direct pre-closing notice from private equity groups, hedge funds, and MSOs, and codifying corporate-practice restrictions, and enforcement has already begun, with the California Attorney General announcing a settlement with a dental management services provider under the new rules this spring. Five states passed material-change notice laws in 2025, and Hawaii, Indiana, New York, Pennsylvania, Rhode Island, Vermont, and Virginia opened 2026 with proposed legislation tightening oversight of healthcare transactions (Ropes & Gray; Nixon Peabody). In parallel, public-sector grant programs are channeling funds toward rebuilding the clinical workforce pipeline and supporting regional health-tech innovation.

The Revere POV. Regulatory headwinds for consolidators are tailwinds for compliance technology. Every DSO contemplating a 2026–2027 recapitalization now needs to demonstrate clean coding and billing, defensible clinical governance, and standardized, interoperable data, months before a banker is ever engaged. Startups that automate coding audits, enforce data interoperability standards, and systematically de-risk DSO portfolios ahead of exits are prime investment targets. We expect compliance tech to be one of the fastest-growing dental software verticals of the next three years, precisely because it is now a precondition for the industry’s largest transactions.

The Bottom Line: Where Revere Partners Goes From Here

The through-line across all five forces is the same: dentistry’s fundamentals are strong, but its margins for error are gone. Practices must produce more with fewer people; patients must be convinced, not just diagnosed; consolidators must prove their platforms are both efficient and compliant. 

As the first venture fund dedicated exclusively to oral health, with a portfolio spanning AI diagnostics, fintech, practice operations, and clinical innovation, we sit at the intersection of every trend described above. We invest in the founders building the efficiency layer, the trust layer, and the compliance layer of modern dentistry and we connect them to the operators, DSOs, and strategics who need them most.